Novocure Ltd (NVCR)vsStryker Corporation (SYK)
NVCR
Novocure Ltd
$15.51
+1.04%
HEALTHCARE · Cap: $2.09B
SYK
Stryker Corporation
$275.56
+2.06%
HEALTHCARE · Cap: $105.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 3595% more annual revenue ($25.84B vs $699.19M). SYK leads profitability with a 14.4% profit margin vs -21.2%. SYK earns a higher WallStSmart Score of 67/100 (B-).
NVCR
Avoid29
out of 100
Grade: F
SYK
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+81.5%
Fair Value
$56.59
Current Price
$15.51
$41.08 discount
Margin of Safety
-19.9%
Fair Value
$229.73
Current Price
$275.56
$45.83 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
15.6% revenue growth
Large-cap with strong market position
Strong operational efficiency at 27.0%
Earnings expanding 44.1% YoY
Generating 1.1B in free cash flow
Areas to Watch
Weak financial health signals
ROE of -52.3% — below average capital efficiency
Earnings declined 6.0%
Distress zone — elevated risk
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVCR
The strongest argument for NVCR centers on Revenue Growth. Revenue growth of 15.6% demonstrates continued momentum.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap, Operating Margin, EPS Growth. PEG of 1.15 suggests the stock is reasonably priced for its growth.
Bear Case : NVCR
The primary concerns for NVCR are Piotroski F-Score, Return on Equity, EPS Growth.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
NVCR profiles as a growth stock while SYK is a value play — different risk/reward profiles.
NVCR carries more volatility with a beta of 1.01 — expect wider price swings.
NVCR is growing revenue faster at 15.6% — sustainability is the question.
SYK generates stronger free cash flow (1.1B), providing more financial flexibility.
Bottom Line
SYK scores higher overall (67/100 vs 29/100). NVCR offers better value entry with a 81.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novocure Ltd
HEALTHCARE · MEDICAL DEVICES · USA
NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?